10-K: Filana Therapeutics Pivots to TSC, Faces Clinical Hold

Filana Therapeutics, formerly Cassava Sciences, has discontinued its Alzheimer's program, pivoted to TSC-related epilepsy, and faces a clinical hold on its lead candidate, simufilam, while settling significant legal claims.

Summary

• Filana Therapeutics, Inc. (formerly Cassava Sciences, Inc.) has shifted its primary focus from Alzheimer's disease to Tuberous Sclerosis Complex (TSC)-related epilepsy, discontinuing all Alzheimer's clinical trials for simufilam by Q2 2025 after both Phase 3 studies (RETHINK-ALZ and REFOCUS-ALZ) failed to meet efficacy endpoints.
• The company's lead therapeutic candidate, simufilam, is now being developed for TSC-related epilepsy, targeting the modulation of filamin A activity.
• Positive preclinical results in a mouse model of TSC-related epilepsy showed simufilam attenuated the progression of seizure activity with a statistically significant dose correlation.
• The U.S. Food and Drug Administration (FDA) has placed a full clinical hold on the planned proof-of-concept clinical trial for simufilam in TSC-related epilepsy as of December 15, 2025, requesting additional preclinical data and protocol modifications.
• The company no longer expects to initiate the TSC-related epilepsy clinical trial in the first half of 2026 due to the FDA clinical hold.
• Filana Therapeutics settled an SEC investigation in September 2024, paying a civil monetary penalty of $40 million in November 2024.
• The U.S. Department of Justice (DOJ) Fraud Section closed its inquiry into the company regarding research misconduct allegations on February 18, 2026, following the dismissal of an indictment against a former scientific collaborator on October 23, 2025.
• A binding term sheet was accepted on December 19, 2025, to settle certain securities class action litigation for $31.25 million, which was recorded as a loss contingency.
• The company reported a net loss of $90.973 million for the year ended December 31, 2025, and an accumulated deficit of $496.1 million.
• Cash and cash equivalents stood at $95.5 million as of December 31, 2025, which management believes is sufficient to fund operations for at least the next 12 months.
• Research and development expenses decreased significantly to $26.6 million in 2025 from $69.6 million in 2024, primarily due to the discontinuation of the Alzheimer's program.
• General and administrative expenses were $68.8 million in 2025, including a $31.3 million securities litigation loss contingency and $4 million in other litigation contingencies, partially offset by a $40 million SEC-related loss contingency recorded in 2024 and $9.9 million in insurance recoveries in 2024.
• An at-the-market (ATM) offering program was established on November 12, 2025, to sell up to $50 million in common stock, with no sales made under this program in 2025.
• The company implemented a workforce reduction of 10 employees (33%) on January 7, 2025, aligning human capital resources with strategic goals after the Alzheimer's program discontinuation.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with a negative sentiment due to the complete failure and discontinuation of the Alzheimer's program, the immediate clinical hold on the new lead program for TSC-related epilepsy, and significant ongoing litigation costs, despite some positive preclinical data and resolution of past investigations.

Positives

• Positive preclinical results for simufilam in a well-accepted mouse model of TSC-related epilepsy, showing attenuation of seizure activity progression with a statistically significant dose correlation.
• Secured exclusive worldwide rights to Yale University's intellectual property for simufilam in TSC-related epilepsy through a license agreement on February 26, 2025.
• The U.S. Department of Justice (DOJ) Fraud Section closed its inquiry into the company regarding allegations of research misconduct on February 18, 2026.
• The indictment against former scientific collaborator Dr. Hoau-Yan Wang was dismissed with prejudice on October 23, 2025, permanently terminating the case.
• Settled an SEC investigation in September 2024, resolving allegations of disclosure violations.
• Reached a binding term sheet on December 19, 2025, to settle significant securities class action litigation for $31.25 million, providing full releases for the company and its officers.
• The CIB Derivative Action was dismissed with prejudice on January 24, 2025, following a settlement.
• Simufilam demonstrated a favorable safety profile in over 2,000 patients during the now-discontinued Alzheimer's disease clinical trials, with no drug-related serious adverse events observed.
• Management believes current cash and cash equivalents of $95.5 million are sufficient to fund operations for at least the next 12 months.

Negatives

• The FDA placed a full clinical hold on the planned proof-of-concept clinical trial for simufilam in TSC-related epilepsy on December 15, 2025, requiring additional preclinical data and protocol modifications.
• The company no longer expects to initiate the TSC-related epilepsy clinical trial in the first half of 2026 due to the clinical hold.
• Both Phase 3 clinical trials (RETHINK-ALZ and REFOCUS-ALZ) for simufilam in Alzheimer's disease failed to meet their pre-specified efficacy endpoints, leading to the discontinuation of the program.
• Incurred a significant net loss of $90.973 million for the year ended December 31, 2025, and has an accumulated deficit of $496.1 million.
• Ongoing legal proceedings, including securities class actions and shareholder derivative actions, continue to incur significant legal expenses and divert management attention.
• The company relies on a single-source supplier (Evonik Industries AG) for simufilam drug substance, posing supply chain risks.
• Discontinued the development of its diagnostic product candidate, SavaDx, in mid-2025.
• Implemented a workforce reduction of 10 employees (33%) on January 7, 2025, indicating operational challenges and a need to conserve resources.
• Expects a modest net loss on leasing activities in 2026 due to higher vacancy rates in its Austin office complex.

Risks

• Product candidates are subject to significant development risks, and regulatory approval or commercial success may never be achieved.
• The FDA's full clinical hold on planned clinical studies for TSC-related epilepsy may delay drug development efforts and harm the business.
• Product candidates are based on new scientific approaches and novel technology, making it difficult to predict development time, cost, and likelihood of success.
• The drug development process, clinical trial process, and patient enrollment/retention can be challenging, expensive, and time-consuming, especially for rare indications like TSC-related epilepsy.
• Heavy dependence on the success of simufilam; if unsuccessful, the company will be unable to generate product revenue.
• Limited operating history in TSC-related epilepsy and no history of product approvals for commercial sale make future success and viability difficult to evaluate.
• Inability to obtain orphan drug exclusivity for product candidates in the U.S. or EU could adversely affect commercialization.
• Inability to develop age-appropriate formulations of simufilam for pediatric patients under 12 could delay or prevent clinical trials in that population.
• Preclinical and early-stage clinical trial results for simufilam are not sufficient evidence of drug safety or efficacy for regulatory approval and may not be reproduced in later-stage studies.
• Substantial delays in clinical studies or inability to complete them on expected timelines could occur.
• Governmental actions regarding U.S. drug prices (e.g., Inflation Reduction Act) could negatively impact the business by reducing prices or increasing compliance obligations.
• Lack of physician and patient acceptance and use of drugs, if approved, would prevent sufficient product revenues.
• Lack of in-house manufacturing or commercialization capabilities and reliance on third-party manufacturers and service providers pose risks to supply, quality, and timely commercialization.
• Unfavorable results of legal proceedings, government investigations, or allegations could adversely impact financial condition and operating results.
• Inability to obtain and maintain sufficient patent protection for product candidates could allow competitors to develop similar products.
• Issued patents covering product candidates could be found invalid or unenforceable if challenged.
• Failure to obtain patent term extension and data exclusivity could materially harm the business.
• Inability to protect the confidentiality of trade secrets would harm the business and competitive position.
• Internal computer systems or those of third parties may fail or suffer cyberattacks, compromising data and disrupting operations.
• Business disruptions and lack of appropriate commercial insurance could harm future revenue and financial condition.
• Social media platforms present risks of brand damage, information leakage, and reputational harm.
• High dependence on key personnel; inability to attract, motivate, and retain qualified personnel could hinder business strategy.
• Termination of relationships with research collaborators or scientific advisors could adversely affect business operations.
• Business may be impacted by political events, war, terrorism, and other geopolitical uncertainties.
• Significant net losses incurred since inception and anticipated for the foreseeable future.
• Broad discretion in the use of capital resources, which may not be used effectively.
• No product revenues and may never achieve profitability based on product revenues.
• Need for additional capital to fund operations and complete product development; failure to obtain capital could force delays or termination of programs.
• Global credit and financial market conditions could negatively impact the value of cash equivalents and financing objectives.
• Market price of common stock has historically been highly volatile and is expected to continue to be volatile.
• Changes in ownership could limit the ability to utilize net operating loss carryforwards.
• Estimates and judgments in financial statements could prove inaccurate, potentially leading to restatements and litigation.
• Anti-takeover provisions in charter documents and Delaware law may prevent or delay removal of incumbent management or a change of control.
• Exclusive forum provisions in bylaws could limit stockholders' ability to obtain a favorable judicial forum.

Future Outlook

The company expects research and development expenses to decrease in future periods as the Alzheimer's disease development program was completed in Q2 2025, and expenses for the TSC-related epilepsy program are expected to be significantly lower. General and administrative expenses are also expected to decrease significantly due to the resolution of legacy litigation, though professional fees and legal expenses related to other ongoing litigation, and higher stock-based compensation, will keep G&A elevated compared to historic levels. The company anticipates a modest net loss on leasing activities in 2026 due to higher vacancy rates. The timing for initiation of the TSC-related epilepsy clinical trial is uncertain and depends on satisfactorily addressing the FDA's clinical hold requests. The company believes its current cash and cash equivalents will be sufficient to fund projected operations for at least the next 12 months but may seek additional future funding through public or private financing.

Management Comments

• Management believes that the current working capital position will be sufficient to meet the company's working capital needs for at least the next 12 months.
• The company is working expeditiously to address the items identified in the FDA's clinical hold letter for the TSC-related epilepsy trial.
• The workforce reduction was intended to align human capital resources to meet strategic goals, in light of the discontinuation of clinical trials for Alzheimer's disease.

Industry Context

StockSavvy.ai notes that Filana Therapeutics' pivot from Alzheimer's disease to TSC-related epilepsy reflects a common strategy in the biotech industry where companies re-evaluate pipelines following clinical trial failures. The shift to a rare neurological disorder like TSC-related epilepsy, which affects approximately 50,000 people in the U.S., positions the company in an orphan drug market, potentially offering regulatory advantages like orphan drug designation, but also presents challenges in patient recruitment for clinical trials. The reliance on modulating filamin A represents a novel mechanistic approach, differentiating it from existing mTOR inhibitors and traditional anti-seizure medications. The clinical hold by the FDA, however, highlights the inherent regulatory hurdles and high-risk nature of novel drug development, particularly in CNS disorders, which often face stringent safety and efficacy requirements.

Comparison to Industry Standards

• The failure of simufilam in two Phase 3 Alzheimer's trials is not uncommon in the highly challenging neurodegeneration space, where many promising candidates from companies like Biogen (Aduhelm, Leqembi) and Eli Lilly (Donanemab) have faced significant hurdles or mixed results, often after substantial investment.
• The pivot to TSC-related epilepsy, a rare disease, aligns with a trend among biopharmaceutical companies to target smaller, underserved patient populations where regulatory pathways might be more streamlined (e.g., orphan drug designation) and competition less intense, similar to strategies employed by companies like Sarepta Therapeutics (Duchenne muscular dystrophy) or Alexion Pharmaceuticals (rare diseases).
• The preclinical data for simufilam in TSC-related epilepsy, showing statistically significant attenuation of seizure activity in a mouse model, is a positive early indicator, but as noted in the filing, preclinical results are not predictive of human clinical trial success, a common challenge across the industry.
• The FDA's clinical hold on the TSC-related epilepsy trial is a significant setback, comparable to regulatory delays or halts experienced by other biotech firms, emphasizing the rigorous scrutiny applied to novel CNS therapies.
• Existing pharmacological treatments for TSC-related epilepsy include traditional anti-seizure medications (e.g., Vigabatrin, Levetiracetam, Valproate, Clobazam) and disease-specific ASMs like Afinitor Disperz (everolimus, an mTOR inhibitor) and Epidiolex (cannabidiol). Simufilam's novel filamin A modulation approach aims to offer a differentiated mechanism of action compared to these established therapies.

Management Changes

Corporate Governance

Legal Proceedings

• **SEC Investigation Settlement**: The company settled an SEC investigation regarding disclosures related to its Phase 2b clinical trial of simufilam for Alzheimer's disease. A final consent judgment was entered on October 18, 2024, requiring the company to pay a civil monetary penalty of $40 million in November 2024. The company neither admitted nor denied the allegations.
• **DOJ Inquiry Closure**: The U.S. Department of Justice Fraud Section notified the company on February 18, 2026, that it had closed its inquiry into allegations of research misconduct, following the dismissal with prejudice of the indictment against former scientific collaborator Dr. Hoau-Yan Wang on October 23, 2025.
• **Consolidated Securities Class Action Settlement**: The company and one of its officers accepted a binding term sheet on December 19, 2025, to settle the Consolidated Securities Action for $31.25 million. This settlement, once formally approved, will provide full and complete releases for the company and its officers. A loss contingency of $31.25 million was recorded as of December 31, 2025.
• **Shareholder Derivative Actions**: Multiple shareholder derivative actions, alleging breaches of fiduciary duty and securities law violations, are ongoing. Some have been consolidated or stayed. The company has indemnification obligations to the individual defendants in these cases. The outcome and potential losses are currently unpredictable.
• **CIB Derivative Action Settlement**: A shareholder derivative action related to the 2020 Cash Incentive Bonus Plan was settled, with the Delaware Court of Chancery entering a Final Order and Judgment approving the settlement and dismissing the action with prejudice on January 24, 2025. The company paid $1.0 million in attorneys' fees and expenses in February 2025.
• **Anti-SLAPP Lawsuit Settlement**: The company and two former officers entered comprehensive settlement agreements with intervenor plaintiffs and another potential plaintiff in an Anti-SLAPP lawsuit, paying approximately $2.5 million in October 2025. The company intends to vigorously defend claims by remaining plaintiffs.

Related Party Transactions

• **Former President and Chief Executive Officer Severance**: Upon resignation on July 15, 2024 (effective September 13, 2024), the former President and CEO received severance compensation of $1.23 million, paid ratably over twelve months. No severance was recognized in 2025.
• **Former Senior Vice President, Neuroscience Severance**: Upon stepping down on July 16, 2024, the former SVP, Neuroscience (spouse of former CEO) received severance compensation of $0.5 million, paid in quarterly installments over twelve months. No severance was recognized in 2025.
• **Consulting Agreement with Former SVP, Neuroscience**: A one-year consulting agreement was entered into on July 16, 2024, with the former SVP, Neuroscience. The company incurred fees of $20,000 in 2025 and $43,000 in 2024. The agreement terminated in July 2025.
• **Consulting Agreement with Former Chief Medical Officer**: A one-year consulting agreement was entered into on June 20, 2025, with the former Chief Medical Officer. The company incurred fees of $42,000 in 2025.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from potential future equity raises (ATM program) and have experienced substantial stock price volatility. Ongoing litigation and past failures of the Alzheimer's program have negatively impacted shareholder value. The $31.25 million settlement of securities litigation will reduce cash resources.
• **Employees**: Experienced a workforce reduction of 33% (10 employees) in January 2025 due to the discontinuation of the Alzheimer's program, impacting job security and morale. The company's ability to attract and retain highly qualified personnel is critical but challenged by past events and ongoing risks.
• **Patients (TSC-related epilepsy)**: The clinical hold on simufilam's proof-of-concept trial means delays in potential new treatment options for a population with high unmet medical needs, particularly those with treatment-resistant seizures.
• **Creditors**: The company's accumulated deficit and ongoing net losses indicate a reliance on existing cash and future financing, which could impact creditworthiness if not managed effectively.
• **Regulatory Authorities**: The FDA's clinical hold and past SEC settlement highlight the company's need to rigorously adhere to regulatory standards and disclosure requirements, impacting future interactions and approval processes.

Next Steps

• Address the FDA's requests for additional preclinical data and modify the protocol design to lift the clinical hold on the TSC-related epilepsy trial.
• Present data and analyses from the positive preclinical study of simufilam in TSC-related epilepsy at an upcoming scientific conference and publication.
• Continue to explore other potential indications for simufilam, both CNS related and otherwise.
• Potentially raise additional capital through the at-the-market (ATM) offering program or other financing sources.
• Prepare a formal stipulation of settlement and motion for preliminary approval for the $31.25 million securities class action settlement.

Key Dates

Recommendation

A 'hold' recommendation is appropriate given the significant uncertainties and risks, balanced by the company's strategic pivot and some positive developments. The discontinuation of the Alzheimer's program and the immediate clinical hold on the new TSC-related epilepsy program are major setbacks, indicating substantial development risk. However, the positive preclinical data for simufilam in TSC, the resolution of the SEC and DOJ investigations, and the settlement of a major securities class action remove some overhangs. The company has sufficient cash for the next 12 months, but future capital raises are likely. Investors should await further clarity on the FDA clinical hold and the progress of the TSC program before making further investment decisions, as the path to commercialization remains long and uncertain.

Keywords

Filana Therapeutics, TSC-related epilepsy, Simufilam, Clinical hold, Biotechnology, CNS disorders, Drug development, SEC settlement, DOJ inquiry, Securities litigation, Orphan drug, Filamin A, Nasdaq Capital Market, 10-K filing, Biopharmaceutical